Due to patent disputes, Furui shares (13.350, 0.00, 0.00%) (300049) and fellow Heisker entered a long-standing patent warfare since 2014. Both sides’ war is not limited to the domestic, and even spread to Germany. On the evening of April 2, the District Court of Düsseldorf, Germany, took a final verdict on a patent infringement case between the two parties and ended with the victory of Furui.
It is understood that the cause of this case was from November 16 to November 19, 2015. Heskell took part in the medical expo held in Düsseldorf, Germany, and publicly displayed the alleged infringement of France. Echosens and its wholly-owned subsidiary Elasticity Measurement System elastically promote the company (SéISME) patented products.
According to reports, Echosens is a holding subsidiary of Furui shares. Echosens sued Heisker infringement on November 18, 2015, at the Düsseldorf District Court in Germany.
The District Court of Düsseldorf, Germany, issued a judgment of first instance on April 20, 2017, which determined that Haskell could not manufacture, sell, circulate, and/or use and/or introduce and/or possess infringements in Germany. The imaging device of the SéISME company's patent No. EP1169636 B1, otherwise it will be fined up to 250,000 euros, or its related directors will receive months of imprisonment.
Subsequently, Heisker expressed dissatisfaction with the verdict and appealed to the District Court of Düsseldorf. Recently, the Düsseldorf District High Court rejected Heisker’s appeal in the final judgment. Hesker was not allowed to appeal and the case was settled.
However, there was a final word in the final judgment that the word 'produced' in the judgment of the first instance was deleted. This may mean that although Haskell cannot be sold in Germany, circulation and/or use and/or follow instructions The purpose of introducing and/or possessing an imaging device that infringes SéISME's patent No. EP1169636 B1, but may retain the qualification for production-related devices.
In fact, the patent warfare between Forrex and Heisker was even more intense in China. In September 2014, Echosens subsidiary Echo Medical filed a lawsuit against Beijing City’s No. 1 Intermediate People’s Court for Heisker’s unfair competition. At the same time, several lawsuits were filed in the Intermediate People's Court of Henan Xuchang City Intermediate People's Court of Zhengzhou City, Henan Province.
Both parties’ lawsuits came to me and they were appealed from the Beijing No. 1 Intermediate People’s Court to the Beijing High People’s Court. In January 2016, the Beijing Higher People’s Court made a final judgment that identified Heiskel’s part of its products. The propaganda language was false propaganda and constituted unfair competition. All of Heisker's appeals were rejected, and the final victory of Freemont ended.
Looking at the background of the struggle between the two sides, it actually stems from the trend of non-invasive liver fibrosis detection technology that has gradually become clinically recognized in China in the past few years. The non-invasive liver fibrosis detection equipment market has also evolved from an exclusive monopoly to a number of competitive landscapes.
Although Furui shares won many times in patent warfare, it is no longer a technical monopolist in the market. Public information shows that the non-invasive diagnostic system of Heisker's core product, FibroTouch Liver Fibrosis, has reached nearly one thousand in China. The grade hospital became one of the leaders in the liver disease detection market in China. The Forrex shares performed tepidly. In the first three quarters of this year, net profit also dropped by 8.07% year-on-year.